Key Financial Inc’s Xilio Therapeutics XLO Stock Holding History

Key Financial Inc’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$565	Hold	59	–	–	﹤0.01%	1257
2026 Q1	$496	Hold	59	–	–	﹤0.01%	1306
2025 Q4	$531	Hold	59	–	–	﹤0.01%	1324
2025 Q3	$691	Hold	59	–	–	﹤0.01%	1309
2025 Q2	$564	Hold	59	–	–	﹤0.01%	1315
2025 Q1	$601	Hold	59	–	–	﹤0.01%	1269
2024 Q4	$793	Hold	59	–	–	﹤0.01%	1253
2024 Q3	$654	Hold	59	–	–	﹤0.01%	1234
2024 Q2	$786	Hold	59	–	–	﹤0.01%	1207
2024 Q1	$896	Hold	59	–	–	﹤0.01%	1195
2023 Q4	$456	Hold	59	–	–	﹤0.01%	1240
2023 Q3	$1.75K	Hold	59	–	–	﹤0.01%	1127
2023 Q2	$2.17K	Hold	59	–	–	﹤0.01%	1153
2023 Q1	$2.63K	Buy	+59	New	+$2.59K	﹤0.01%	918

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Key Financial Inc's XLO Position: Q2 2026 in Review

Key Financial Inc held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 59 shares worth $565. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

Key Financial Inc first reported a position in XLO in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.63K in Q1 2023. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

Key Financial Inc held 59 shares of Xilio Therapeutics worth $565 as of Q2 2026.
Key Financial Inc left its Xilio Therapeutics share count unchanged in Q2 2026.
Xilio Therapeutics made up ﹤0.01% of Key Financial Inc's portfolio in Q2 2026, its #1257 holding.
Key Financial Inc first reported a position in Xilio Therapeutics in Q1 2023 and has held it in 14 quarters since.
Key Financial Inc's Xilio Therapeutics position peaked at $2.63K in Q1 2023.
26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Key Financial Inc's 13F filing for Q2 2026, filed 24 Jul 2026.